thalidomide has been researched along with Leukemia, Myeloid in 16 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| " Among the putative inhibitors of angiogenesis, thalidomide has demonstrated a considerable efficacy in myelodysplastic syndromes (MDS) and AML with overall response rates up to 56% and 25%, respectively." | 4.82 | Thalidomide for the treatment of acute myeloid leukemia. ( Berdel, WE; Bieker, R; Kessler, T; Kienast, J; Mesters, RM; Padró, T; Steins, MB, 2003) |
| "Thalidomide in combination with chemotherapy is an alternative treatment option for elderly patients with AML." | 2.87 | Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia. ( Chen, C; Xu, W; Yang, J, 2018) |
| "Patients ≥ 60 years of age with untreated acute myeloid leukemia received azacitidine 75 mg/m2 for 7 days followed by escalating doses of lenalidomide daily for 21 days starting on day 8 of each cycle every 6 weeks." | 2.78 | Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. ( Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B, 2013) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| " Overall, adverse events were fatigue, constipation, rash, and neuropathy (grade 1 to 2 in most patients)." | 2.70 | Efficacy and safety of thalidomide in patients with acute myeloid leukemia. ( Berdel, WE; Bieker, R; Buechner, T; Kessler, T; Kienast, J; Kropff, M; Mesters, RM; Padró, T; Ruiz, S; Steins, MB, 2002) |
| "Thalidomide is a putative anti-angiogenesis agent that has significant anti-tumour activity in haematological malignancies with increased bone marrow angiogenesis, including multiple myeloma (MM) and myelodysplastic syndromes (MDS)." | 1.32 | Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. ( Albitar, M; Cortes, J; Estey, E; Faderl, S; Giles, FJ; Kantarjian, H; Keating, M; O'Brien, S; Thomas, DA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braulke, F | 1 |
| Schulz, X | 1 |
| Germing, U | 1 |
| Schuler, E | 1 |
| Platzbecker, U | 1 |
| Nolte, F | 1 |
| Hofmann, WK | 1 |
| Giagounidis, A | 1 |
| Götze, K | 1 |
| Lübbert, M | 1 |
| Schlenk, RF | 1 |
| Schanz, J | 1 |
| Bacher, U | 1 |
| Ganser, A | 1 |
| Büsche, G | 1 |
| Letsch, A | 1 |
| Schafhausen, P | 1 |
| Bug, G | 1 |
| Brümmendorf, TH | 1 |
| Haas, R | 1 |
| Trümper, L | 1 |
| Shirneshan, K | 1 |
| Haase, D | 1 |
| Chen, C | 1 |
| Yang, J | 1 |
| Xu, W | 1 |
| Basile, FG | 1 |
| Stone, RM | 1 |
| Schmidt-Hieber, M | 1 |
| Dabrowski, R | 1 |
| Weimann, A | 1 |
| Aicher, B | 1 |
| Lohneis, P | 1 |
| Busse, A | 1 |
| Thiel, E | 1 |
| Blau, IW | 1 |
| Breccia, M | 1 |
| Cannella, L | 1 |
| Latagliata, R | 1 |
| Nanni, M | 1 |
| Santopietro, M | 1 |
| Loglisci, G | 1 |
| Ferretti, A | 1 |
| Barzotti, R | 1 |
| Oliva, EN | 1 |
| Alimena, G | 1 |
| Landgren, O | 1 |
| Thomas, A | 1 |
| Mailankody, S | 1 |
| Pollyea, DA | 1 |
| Zehnder, J | 1 |
| Coutre, S | 1 |
| Gotlib, JR | 1 |
| Gallegos, L | 1 |
| Abdel-Wahab, O | 1 |
| Greenberg, P | 1 |
| Zhang, B | 1 |
| Liedtke, M | 1 |
| Berube, C | 1 |
| Levine, R | 1 |
| Mitchell, BS | 1 |
| Medeiros, BC | 1 |
| Badros, A | 1 |
| Morris, C | 1 |
| Zangari, M | 1 |
| Barlogie, B | 1 |
| Tricot, G | 1 |
| Estey, EH | 1 |
| Thall, PF | 1 |
| Kropff, MH | 1 |
| Lang, N | 1 |
| Bisping, G | 1 |
| Dominé, N | 1 |
| Innig, G | 1 |
| Hentrich, M | 1 |
| Mitterer, M | 1 |
| Südhoff, T | 1 |
| Fenk, R | 1 |
| Straka, C | 1 |
| Heinecke, A | 1 |
| Koch, OM | 1 |
| Ostermann, H | 1 |
| Berdel, WE | 3 |
| Kienast, J | 3 |
| Steins, MB | 2 |
| Bieker, R | 2 |
| Padró, T | 2 |
| Kessler, T | 2 |
| Mesters, RM | 2 |
| Thomas, DA | 1 |
| Estey, E | 1 |
| Giles, FJ | 1 |
| Faderl, S | 1 |
| Cortes, J | 1 |
| Keating, M | 1 |
| O'Brien, S | 1 |
| Albitar, M | 1 |
| Kantarjian, H | 1 |
| Mesa, RA | 1 |
| Tefferi, A | 1 |
| Li, CY | 1 |
| Steensma, DP | 1 |
| Lancet, JE | 1 |
| List, AF | 1 |
| Moscinski, LC | 1 |
| Ruiz, S | 1 |
| Kropff, M | 1 |
| Buechner, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1-2 Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia[NCT00890929] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Early death was assessed as death within 28 days of the start of treatment" (NCT00890929)
Timeframe: 28 days
| Intervention | percentage of subjects remaining alive (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 83 |
Compete Remission (CR) includes subjects with CR but incomplete recovery of blood counts (CRi). CR was assessed according to the European LeukemiaNet (ELN) guidelines, and is defined as the absence of clonal lymphocytes in the peripheral blood. (NCT00890929)
Timeframe: 12 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 28 |
The maximum tolerated dose (MTD) of lenalidomide was determined in study phase 1, for use in study Phase 2 (not conducted). The outcome is reported as the dose of lenalidomide that represents the MTD. (NCT00890929)
Timeframe: 15 months
| Intervention | mg/day lenalidomide (oral) (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 50 |
OS from the start of treatment of responders (per ELN guidelines) was assessed at a median follow up of 88 weeks from the end of treatment (range, 1-120), and was censored at 1 April 2012. (NCT00890929)
Timeframe: 88 weeks (median)
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 69 |
ORR includes subjects with CR, CRi, and partial response (PR). Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 26 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 41 |
OS from the start of treatment was assessed at a median follow up of 88 weeks from the end of treatment (range, 1-120), and was censored at 1 April 2012. (NCT00890929)
Timeframe: 88 weeks (median)
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 20 |
Responses and remission were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 26 months
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 6 |
CR includes subjects with CR but incomplete recovery of blood counts (CRi). Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 18 weeks
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 12 |
Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 36 weeks
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 6 |
2 reviews available for thalidomide and Leukemia, Myeloid
| Article | Year |
|---|---|
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5 | 2009 |
Thalidomide for the treatment of acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow; | 2003 |
5 trials available for thalidomide and Leukemia, Myeloid
| Article | Year |
|---|---|
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, CD34; Chromosome B | 2017 |
Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; | 2013 |
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem | 2003 |
Efficacy and safety of thalidomide in patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Dose-Response Relation | 2002 |
9 other studies available for thalidomide and Leukemia, Myeloid
| Article | Year |
|---|---|
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidin | 2009 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bor | 2012 |
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Ch | 2011 |
Myeloma and second primary cancers.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelody | 2011 |
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2002 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothe | 2003 |
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers; Fibroblast Growt | 2003 |
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Topics: Acute Disease; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; J | 2006 |
Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; | 2007 |